ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

entecavir

Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.

Drug pageEntecavir: every studyMany companies study it; this page follows only the 32 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 29, 200632 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb240 open or runningphase 4since Aug 29, 2006May 4, 2002none ahead
Hoffmann-La Rocheits history only40 open or runningphase 4since Jan 30, 2008Jan 30, 2008none ahead
Ascentage Pharma Group Internationalits history only11 open or runningphase 2since Sep 24, 2020Sep 24, 2020none ahead
Aucta Pharmaceuticalsits history only10 open or runningphase 1since Jul 27, 2017Jul 27, 2017none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 4since Jul 26, 2015Jul 26, 2015none ahead
Sino Biopharmaceuticalits history only10 open or runningno phasesince Jan 22, 2019Jan 22, 2019none ahead

Also a collaborator on its studies: ICON Clinical Research and CPR Pharma Services Pty Ltd, Australia.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since May 4, 2002.

  1. Oct 26, 2006Phase 4 study in Hepatitis B, ChronicNCT00393484 · 122 enrolled · Korea, Republic of
  2. Nov 1, 2006Phase 3 study in Hepatitis B, ChronicNCT00395018 · 109 enrolled · United States, Argentina, Australia and more
  3. Dec 11, 20062 phase 3 studies in Hepatitis B, ChronicNCT00410202, NCT00410072
  4. Jan 16, 2007Phase 2 study in Hepatitis B, ChronicNCT00423891 · 64 enrolled · United States, Argentina, Belgium and more
  5. Jan 18, 2008Phase 3 study in Hepatitis B, ChronicNCT00605384 · 4 enrolled · United States, Belgium, Germany and more
  6. Jul 17, 2008Phase 4 study in Hepatitis B, ChronicNCT00718887 · 228 enrolled · China
  7. Sep 8, 2009Phase 3 study in Hepatitis B, ChronicNCT00975091 · 600 enrolled
  8. Sep 29, 2009Phase 4 study in Hepatitis B, ChronicNCT00986778
  9. Nov 24, 20092 phase 2 studies in Hepatitis B, ChronicNCT01020565, NCT01022801
  10. Dec 17, 20092 phase 2 studies in Hepatitis B, ChronicNCT01037166, NCT01037062
  11. Feb 3, 2010Phase 3 study in Hepatitis B, ChronicNCT01063036 · 144 enrolled · France, Germany, Italy and more
  12. Mar 2, 2010Phase 3 study in Hepatitis B, ChronicNCT01079806 · 180 enrolled · United States, Argentina, Belgium and more
  13. Sep 16, 2011Phase 2 study in Hepatitis BNCT01438424 · 1,053 enrolled
  14. Mar 14, 2017Phase 1 study in Hepatitis BNCT03083821 · 6 enrolled · Japan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 24 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03083821Hepatitis B · Japan1CompletedDec 19, 20176
NCT01438424Hepatitis B2CompletedDec 20091,053
NCT01079806Hepatitis B, Chronic · United States, Argentina, Belgium and more3CompletedMar 31, 2013180
NCT01063036Hepatitis B, Chronic · France, Germany, Italy and more3CompletedNov 2012144
NCT01037166Hepatitis B, Chronic · Japan2CompletedFeb 200584
NCT01037062Hepatitis B, Chronic · Japan2CompletedDec 2006282
NCT01022801Hepatitis B, Chronic2CompletedMar 2005120
NCT01020565Hepatitis B, Chronic2CompletedFeb 200560
NCT00986778Hepatitis B, Chronic4WithdrawnDec 20120
NCT00975091Hepatitis B, Chronic3CompletedAug 2007600
NCT00718887Hepatitis B, Chronic · China4CompletedDec 2009228
NCT00605384Hepatitis B, Chronic · United States, Belgium, Germany and more3TerminatedFeb 20094
NCT00423891Hepatitis B, Chronic · United States, Argentina, Belgium and more2CompletedAug 31, 201364
NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more3CompletedJan 2011629
NCT00410072Hepatitis B, Chronic · United States, Argentina, Australia and more3CompletedOct 2010669
NCT00395018Hepatitis B, Chronic · United States, Argentina, Australia and more3CompletedMar 2011109
NCT00393484Hepatitis B, Chronic · Korea, Republic of4CompletedJan 2009122
NCT00371150Hepatitis B · United States, Brazil, Mexico and more4CompletedMar 2011131
NCT00096785Hepatitis B · United States, Canada, Hong Kong and more3CompletedJan 200669
NCT00065507Hepatitis B · United States, Brazil, Canada and more3CompletedOct 2008195
NCT00051038Hepatitis B · United States3CompletedOct 2005
NCT00036608Hepatitis B, Chronic · United States3CompletedFeb 2005
NCT00035789Hepatitis B, Chronic · United States3CompletedMay 2005
NCT00035633Hepatitis B, Chronic · United States3CompletedFeb 2005

How it is read

Names in the registry

  • “Entecavir”, 28 entries
  • “entecavir”, 4 entries
  • “Entecavir (ETV)”, 2 entries
  • “Entecavir + Tenofovir”, 2 entries
  • “P1101 + Nivolumab + Entecavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.